Abbott has entered a definitive agreement with the Solvay Group to acquire Solvay’s pharmaceuticals business for $6.6 billion in cash. The acquisition also includes global rights to the fenofibrate franchise. Currently Abbott has U.S. rights to fenofibrate and pays royalties to Solvay. Belgium-based Solvay Pharmaceuticals will add more than $3 billion in annual sales; the majority outside the U.S. Solvay also has significant presence and infrastructure in high-growth emerging markets, i...